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Abstract
Background: Idiopathic Intracranial Hypertension (IIH) is characterized by an elevation of intracranial pressure (ICP
no identifiable cause. The aetiology remains largely unknown, however observations made in a number of recent
clinical studies are increasing the understanding of the disease and now provide the basis for evidence-based
treatment strategies.
Methods: The Embase, CDSR, CENTRAL, DARE and MEDLINE databases were searched up to 1st June 2018. We
analyzed randomized controlled trials and systematic reviews that investigate IIH.
Results: Diagnostic uncertainty, headache morbidity and visual loss are among the highest concerns of clinicians
and patients in this disease area. Research in this field is infrequent due to the rarity of the disease and the lack of
understanding of the underlying pathology.
Conclusions: This European Headache Federation consensus paper provides evidence-based recommendations
and practical advice on the investigation and management of IIH.
Objective
Idiopathic Intracranial Hypertension (IIH) is character-
ized by an elevation of intracranial pressure (ICP) with
no identifiable cause [1]. Despite the fact that its aeti-
ology remains largely unknown, the observations made
in a significant number of recent clinical studies and the
resulting increase in the understanding of its clinical pic-
ture have led to modifications in its diagnostic classifica-
tion and provide the basis for evidence-based treatment
strategies. This consensus paper is based on the current
literature on diagnosis and treatment of IIH and pro-
vides evidence-based recommendations on its treatment
where randomized-controlled trials are available.
Background
The entire clinical syndrome of IIH is defined in the
diagnostic criteria established by Friedman et al. [2]
(Fig. 1) whereas the associated headache is defined in
the Headache Classification of the International
Headache Society (IHS) [3] (Table 1). The term ‘pseudo-
tumor cerebri’, in the past commonly used as a synonym
for IIH, is now used as an umbrella term that describes
the chronic elevation of ICP regardless of its aetiology
and further subdivides in the primary (IIH) and second-
ary forms [2]. The remit of this manuscript will exclu-
sively focus on the diagnostic and therapeutic algorithm
of primary IIH.
IIH is a disorder that mainly affects obese women of
childbearing age. Its prevalence has been estimated
between 0.5–2 per 100,000 of the general population [4].
However, due to the lack of awareness of the clinical
syndrome as well as its potential similarity to primary
headaches including migraine, it has been suggested that
the disorder may be underdiagnosed [5]. In contrast,
given the strong association between obesity and ele-
vated ICP, it can be expected that the increasing obesity
in the general population will increase the prevalence as
well as the socioeconomic burden of the disease [1, 6].
This outlook underlines the importance of clear diagnos-
tic criteria that allow an accurate diagnostic algorithm as
well as recommending effective management strategies.
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Clinical symptoms and diagnostic algorithm
Clinical picture
Headache
Headache, present in up to 90% of IIH patients, is com-
monly the primary symptom leading IIH patients to seek
medical advice [7, 8]. Headache is also the key factor
driving reduced quality of life in IIH [9]. The features of
IIH-related headache vary substantially and in the con-
text of a limited amount of clinical studies that aim at
characterizing them, the IHS-criteria remain relatively
unspecific in their description. Patients commonly de-
scribe their headache as pressing, explosive with a
frontal, retroorbital localization [3, 10]. Frequently the
headache has a migraine phenotype and overuse of anal-
gesic is observed in over a third of IIH patients [11].
Phenotypic similarities may hamper its distinction from
migraine and other headaches [7, 8, 12–17]. In order to
establish the diagnosis of IIH it is required that the caus-
ality between the clinical symptoms and elevated ICP is
demonstrated by a temporal relationship between head-
ache onset and the identification of elevated ICP or an
alleviation after a reduction of ICP. However, one study
reported that over 20% of patients with other headache
disorders also improve after lumbar puncture (LP) [18].
The second edition of the International Headache Clas-
sification (ICHD-2) detailed headache alleviation after
pressure reduction was a required diagnostic criterion of
IIH, however in the recent ICHD-3 criteria this criterion
has been removed as headache duration can vary sub-
stantially with almost two thirds of IIH-patients com-
plaining of persisting chronic headache despite a
normalization of ICP [3, 10, 18, 19]. However, the pre-
cise onset of increased ICP and the related headache are
difficult to establish, so the preliminary version of the
present diagnostic ICHD-3 criteria (ICHD-3 beta) for
IIH-headache have been field tested in a recent study
and more sensitive and specific criteria have been sug-
gested [18].
Ophthalmic features
Bilateral disc swelling, termed papilloedema when it is
caused by raised ICP, is a cardinal feature of IIH and on
examination it can be asymmetrical in 4% of cases [7, 20–
25]. Examination of the eye can be challenging and in case
of diagnostic uncertainty, papilloedema should be con-
firmed by an experienced ophthalmologist. Exclusion of
pseudopapilloedema is recommended to prevent unneces-
sary investigations and procedures. These include mea-
surements of intraocular pressure, ruling out hypotony,
and critical examination of the optic nerve as small hyper-
metropic discs, titled myopic discs, vitreous traction and
disc drusen can all be mistaken for papilloedema. There is
a high frequency (40%) of diagnostic errors in IIH, with
the main cause being an incorrect ophthalmic examin-
ation [26].
Raised ICP can lead to a number of visual symptoms
including transient visual obscurations, visual blurring
and double vision. All IIH patients with active papilloe-
dema need close ophthalmological monitoring to evalu-
ate the visual function and assess the risk of visual loss
as in some the visual disturbances are progressive and
may lead to prolonged ischemia of the optic nerve head
resulting in complete and irreversible sight loss second-
ary to optic atrophy. The tests of visual function are im-
portant as no correlation between headache frequency
Fig. 1 Diagnostic criteria for IIH (Friedman criteria). Diagnostic criteria for IIH and IIH without papilloedema. Infogram demonstrating the “grey
zone” in which LP pressure is normal in some individuals but can indicate pathologically raised ICP in some. Measurements in the grey zone
need to be interpreted with caution and patients must fit the other criteria for IIH for a diagnosis to be confirmed
Table 1 Diagnostic criteria for IIH-related headache according to
the International Classification of Headache Disorders (ICHD-3)
A. New headache, or a significant worsening of a pre-existing headache,
fulfilling criterion C
B. Both of the following:
1. idiopathic intracranial hypertension (IIH) has been diagnosed
2. cerebrospinal fluid (CSF) pressure exceeds 250 mm CSF (or 280 mm
CSF in obese children)
C. Either or both of the following:
1. headache has developed or significantly worsened in temporal
relation to the IIH, or led to its discovery
2. headache is accompanied by either or both of the following:
a) pulsatile tinnitus
b) papilloedema
D. Not better accounted for by another ICHD-3 diagnosis
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and the degree of papilloedema has been demonstrated
[27]. Data from a recent randomized-controlled clinical
trial with acetazolamide for the treatment of IIH, the
IIH Treatment Trial (IIHTT), revealed that higher-grade
papilloedema and a significant loss in visual acuity at
presentation are associated with a higher risk of progres-
sion to visual field loss despite adequate treatment [28].
Ophthalmic examination should include: visual acuity,
a pupil examination, formal visual field assessment and
dilated fundal examination to evaluate the papilloedema.
The typical visual field findings are that of an enlarge-
ment of the blind spot, peripheral constriction and or an
inferior nasal step or partial arcuate defect [22, 29]
(Fig. 2). To interpret visual fields with confidence a basic
understanding of the plots (Table 2), reliability indices
(Table 3), and global parameters (Table 3) is required.
Visual field testing is a psychophysical test and can be
demanding to interpret in any disease including IIH. Be-
sides physical obstacles, cognitive factors including sub-
ject attention, motivation, fatigue, and response bias can
influence the obtained thresholds. Improvement in reli-
ability has been shown to improve with clear instruc-
tions [30]. Despite clear instructions in the IIHTT,
performance failures were observed at some point in
one fifth of the participants and were likely due to
behavioural factors as the fields returned to baseline
values on re-testing: therefore not deemed to be disease
progression. Retesting is recommended where there is
perimetric worsening, in the presence of unreliable indi-
ces (Table 3) [31].
The role of imaging the optic nerve head is becoming
increasingly important. Qualitative analysis of photo-
graphic images remains useful for clinical records.
Newer techniques such as wide field imaging using the
Optos™ allow high resolution image capture through an
undilated pupil, with a magnification tool to examine
the optic nerve head (Fig. 3). Optical Coherence Tomog-
raphy (OCT), in particular spectral domain OCT, offers
a non-invasive technique for both qualitative and object-
ive quantification of papilloedema that can support the
detection of papilloedema [32–34]. OCT is found to be
a valuable tool for quantification of papilloedema in lon-
gitudinal assessment: Fig. 4 demonstrates the clear im-
provement in papilloedema in a newly diagnosed IIH
patient who undertook a low calorie diet for 6 weeks
[35]. However, OCT has limitations. In cases of severe
papilloedema errors occur in the automated software
analysis which can lead to unreliable values, these scans
need manual adjustment to ensure reliable results [36].
However as peripapillary retinal nerve fibre layer (RNFL)
Fig. 2 Typical visual field defects in IIH. Common visual field defects seen in IIH with the Humphrey visual field analyser grey scale. a, Left eye
with a slightly enlarged blind spot; b, right eye with slightly enlarged blind spot; c, Left eye obvious enlarged blind spot; d, right eye with
enlarged blind spot and paracentral scotoma; e, left eye with enlarged blind spot and prominent inferior nasal step; f, Left eye with enlarged
blind spot, dense superior and inferior arcuate scotomas
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thickness resolves, most systems do not allow the distinc-
tion between reduction in oedema and optic atrophy as
both conditions lead to a reduction in RNFL thickness [37].
Software enhancements on certain OCT platforms allow
the determination of ganglion cell layer thickness and this
may prove to be beneficial to correlate with visual loss.
Some OCT platforms have the ability to capture short video
footage which is useful to document location and presence
of spontaneous venous pulsations (Additional file 1). OCT
imaging supports the diagnosis and monitoring of papilloe-
dema as demonstrated in Fig. 5 where there is an increase
in the volume at the optic nerve head with recurrence of
symptoms of headache and pulsatile tinnitus for one month
in a patient previously in ocular remission, but does not
mitigate the continued monitoring of all measures of visual
function through clinical examination and formal perimetry.
Other symptoms
IIH can cause other symptoms, as well as headache and
visual disturbances. Recent data however suggests that
other systems may also be affected in IIH, presumably as
the result of increased ICP, although the exact mecha-
nisms leading to these alterations remain largely un-
known. In this context, structural changes in the olfactory
nerve [38], which are associated with an olfactory dysfunc-
tion in up to 80% of IIH patients, have been demonstrated
[39, 40]. Nevertheless, despite an easy determination of ol-
factory function by the use of extended Sniffin’ Sticks, this
observation is not useful for the diagnosis or follow-up ex-
aminations in IIH as the effects of a variation in ICP may
reflect on olfactory function with a significant delay.
A uni- or bilateral pulsatile tinnitus is commonly ob-
served in IIH [7, 8, 41]. Its underlying cause is not entirely
elucidated but it is hypothesized that stenoses in the trans-
verse sinus, which are commonly observed in IIH, may in-
duce audible turbulences in blood flow. Nevertheless
further studies are required to confirm this assumption.
Unilateral or bilateral sixth-nerve palsy may occur in IIH
causing horizontal diplopia [42, 43]. The reason for this
neurological deficit in the context of IIH has not been fully
investigated. The pathophysiological mechanism has trad-
itionally been thought to be due to compression against the
Table 2 Interpretation of Humphrey visual field plots. In static perimetry the stimulus is stationary but it changes its intensity until
the sensitivity of the eye at the particular point is found. It is measured at preselected locations in the visual field. Most IIH patients
have a threshold test where steps of 4 dB are used until detected then re-tested at every point in 2 dB steps
Term Explanation Notes
Numerical
Display
These are the raw values of the individual’s retinal sensitivity at
predetermined points in decibels (dB). Normal values are approximately
30 dB while recorded values of < 0 dB equate to no sensitivity measure.
The HVF analyser uses light between 0 and 50 dB (0 is the brightest
and 50 is the dimmest). Sensitivity is greatest in the central field and
decreases towards the periphery.
Grey scale This is a graphical representation of the numerical display. It allows
for quick assessment of the field as values closer to 0 dB (low sensitivity)
are coded with black and those closer to 50 dB with white
(highest sensitivity).
This parameter should not be used alone, the reliability and global
indices are critical to interpreting this map.
Total
deviation
This demonstrates the difference between measured values and
population age-normal values at specific retinal points. The
numbers indicate the difference compared to the mean. A negative
value indicates less visual sensitivity compared to the mean population.
Both the total deviation and the pattern deviation provide a numerical
total plot (top) and the probability plot which gives a visual
representation of statistical analysis (t test) of this deviation from
the mean; the larger departure from the mean, the darker the
symbol.
Pattern
deviation
This represents focal depressed areas in the points tested when
accounting for overall general reductions of vision caused by media
opacities (e.g. cataracts), uncorrected refractive error, reductions in
sensitivity due to age and pupil miosis.
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petrous ligament or the ridge of the petrous temporal bone,
or stretching along the intracranial course of the nerve.
Cognitive function has been reported to be affected in
IIH. While a number of small uncontrolled studies,
which occasionally focused only on single neuropsycho-
logical domains, suggested a relationship between IIH
and cognitive decline [44–46], Yri et al. demonstrated in
an extensive prospective case-control study that IIH is
associated with a global cognitive dysfunction with the
most extensive deficit in reaction time and processing
speed [47]. Interestingly, the results of this study reveal
that despite an improvement of ICP and headache after
3 months of adequate treatment, the cognitive dysfunc-
tion appears to persist raising the question if IIH-related
cognitive decline is the result of more complex mecha-
nisms rather than the direct effect of mechanical com-
pression. These neuropsychological deficits may hamper
significantly a professional reintegration after prolonged
absence from work.
Investigations
Neuroimaging
Brain imaging is an essential part of the diagnostic algo-
rithm and MRI should be considered the gold standard
of care to exclude secondary causes of elevated ICP and
to identify structural alterations associated with IIH.
These include an empty sella turcica (or at least signifi-
cant changes in size, shape and volume of the pituitary
gland) and a flattening of the posterior optic globe. IIH
also leads to an enlargement of the optic nerve sheath
and an increased tortuosity of the optic nerve [12, 48–
51]. However, the volume of the optic nerve is not af-
fected [12]. In contrast to early imaging studies based on
plain film X-ray imaging that suggested a reduced ven-
tricle size (slit-like ventricles) as indicative for IIH [52],
data based on CT and MR imaging techniques demon-
strates that size and volume of the lateral ventricles are
not altered in IIH [49, 53].
Diagnostic brain imaging in IIH should always include
a CT- or MR venography to exclude a venous sinus
thrombosis as even clinically inapparent microthrom-
boses may induce a venous outflow obstruction that in-
creases ICP [54]. Furthermore the venography may
demonstrate the presence of uni- or bilateral transverse
sinus stenoses (TSS) as these are frequently observed in
IIH patients with reported prevalence rates of up to 90%
[51, 55, 56]. However, if TSS are cause or consequence
of elevated ICP remains controversial. Additionally,
Table 3 Interpretation of Humphrey visual field parameters
Term Explanation Notes Example
Reliability indices:
Fixation
Losses
Fixation is plotted, if the patient moves and
the machine re-tests and patient sees spot
then a fixation loss is recorded.
Fixation losses above 20% may significantly
compromise the reliability of the test.
OD- Right eye;
OS – Left eye.
Note the longer the test time the more
tired the patient will be.
False POS
(Positive)
Errors
Patient responds to the normal whirr noise of
the computer when it sounds as if is about to
present a light but does not.
High false positive score occur in a
“trigger happy” patient. < 33% is an
unacceptable test.
False NEG
(Negative)
Errors
A brighter light is presented in an area in which
the threshold has already been determined and
the patient does not respond to it.
High false negative score occurs in fatigued
or inattentive patients. < 33% is
an unacceptable test.
Global indices:
Glaucoma
Hemifield
Test (GHT)
This assesses clusters of points above and
below the horizontal meridian for any
significant difference.
It describes the field as “Within normal
limits”, “Borderline” or “Outside normal limits”
24–2 denotes the test strategy
(24 degrees temporally and 30 degrees
nasally and tests 54 points).
VFI
Mean
deviation
(MD)
A measure of overall field loss
Pattern
standard
deviation
(PSD)
Measure of focal loss or variability within the
field taking into account any generalised
depression.
An increased PSD is more indicative of
glaucomatous field loss than MD.
Probability
values
These indicate the significance of the defect
< 5%, < 2%, < 1% and 0.5%.
The lower the p value the greater its clinical
significance and the lesser the likelihood of
the defect occurring by chance.
Reference: Mollan, SP (2018). Investigations and their interpretation. In Denniston AK and Murray PI, 4thed., Oxford handbook of ophthalmology: Oxford University press: Oxford
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asymmetry of the transverse sinus can occur in 50% of
healthy individuals [57].
Despite the value of neuroimaging in the diagnostic
workup of IIH, it does not replace the need for a measure-
ment of lumbar opening pressure as imaging abnormal-
ities show a large interindividual variation and none of the
findings are pathognomonic of IIH hence imaging findings
only serve as supportive evidence for the diagnosis of IIH.
Lumbar puncture
LP is mandatory in the diagnostic algorithm of IIH. In
addition to a normal CSF composition, diagnostic criteria
Fig. 3 Wide-field imaging using. Wide-field imaging with the Optos™ through an undilated pupil in a, normal patient and b, a patient with IIH. a,
normal fundus with blue high magnification box to inspect the optic nerve. Peripapillary atrophy 360o around the disc which is normal. Note the
lashes seen inferiorly as artefact on image. b, right optic nerve which has grade 2 Frisen swelling where there is elevation of the optic disc margin
360o, loss of the clear optic disc margin as seen in a. c, the high magnification tool allows excellent visualisation of the swelling without degradation
of the image
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require that opening pressure, which should be measured
in the lateral decubitus position with stretched legs and
without sedative medications, should not exceed 25
cmH2O in adults and 28 cmH2O in children [2, 58, 59].
Increases of ICP may also occur intermittently, in particu-
lar in IIH patients without papilloedema [60, 61]. There-
fore, if IIH is suspected but opening pressure lies within
the normal range during the initial assessment, a second
measurement or even continuous monitoring could be
considered [61–63]. Conversely, pressures above 25
cmH2O can occur in normality [64], with pressures in the
range 25–30 cmH2O constituting a grey area that could
be pathological or normal and should be interpreted with
caution [43]. Patients with pressures in this “grey zone”
should be evaluated cautiously to ensure they meet the
other aspects of the IIH diagnostic criteria [43].
Blood tests
Blood tests should be performed for the exclusion of
secondary causes of elevated ICP or other medical con-
ditions that may clinically present with similar symp-
toms. Blood test should be tailored to the individual
patient’s presentation. In the absence of typical
phenotypic characteristics of IIH (obese female of child-
bearing age) blood tests to exclude secondary causes of
pseudotumor cerebri are key. Excluding conditions that
increase the likelihood of a sinus vein thrombosis, which
could obstruct venous outflow, may be performed. These
could include analysis of coagulation parameters to iden-
tify hypercoagulable states as well as a search for dis-
eases that are associated with a higher risk of venous
(micro-) thrombosis such as systemic lupus erythemato-
sus and infections of the middle ear or mastoid. Endo-
crine disorders that may mimic IIH symptoms include
Addison’s disease, Cushing’s syndrome, hypoparathyroid-
ism as well as the use of growth hormones and may
need to be excluded. Other medical conditions that may
induce a secondary increase of ICP and should be identi-
fied via serologic examinations include systemic infec-
tions, uraemia, renal failure and anaemia [65] (Table 4).
Treatment
Surgical treatment
Surgical management is essential for IIH patients with rap-
idly declining visual function. The evidence base for choice
Fig. 4 Optical coherence tomography highlighting improvement of papilloedema. OCT is useful for monitoring of changes in papilloedema. a,
Right eye infrared (IR) image of a swollen optic nerve. Note the Paton’s lines (circumferential lines) between 9 o’clock and 11 o’clock. b, Right eye
IR image the nerve following a low calorie diet 6 weeks later. Note the tidemark changes of the extent of the previous oedema. c, Right eye cross-sectional
image half way through the optic nerve head. Note the high line indicates the height of the swelling at diagnosis and the green volume
reduction from the first scan to the most recent one (in this case 6 weeks). d, Left eye IR image of a swollen optic nerve. Note the difference between
a and d, indicating asymmetric papilloedema with worse papilloedema in the left eye. e, Left eye IR image the nerve following a low calorie diet
6 weeks later. Note the tidemark changes of the extent of the previous oedema. f, Left eye cross-sectional image half way through the optic nerve
head. Note the high line indicates the height of the swelling at diagnosis and the green volume reduction from the first scan to the most recent one
(in this case 6 weeks)
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Fig. 5 (See legend on next page.)
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of surgical technique is lacking and practice varies inter-
nationally and with surgeon preference. CSF diversion pro-
cedures including ventriculo-peritoneal, lumbo-peritoneal,
and less frequently ventriculo-atrial shunting may be uti-
lised. Ventriculo-peritoneal shunts are preferred due to
lower revision rates compared to lumbo-peritoneal shunts
(1.8 versus 4.3 revisions per patient respectively) [66].
Ventriculo-peritoneal shunts are typically placed using
neuro-navigation and adjustable valves (anti-gravity or
anti-siphon devices) that can reduce the risk of low pres-
sure headaches [66]. However, ventriculo-peritoneal shunt
insertion leads to a temporary driving restriction in some
countries such as the United Kingdom. Lumbo-peritoneal
shunting may be considered but should be avoided in those
with low lying cerebellar tonsils due to the risk of
post-operative cerebellar tonsillar descent. Shunt revision is
common with 51% requiring revision and multiple revisions
required in 30% [67]. Complications can occur including
abdominal pain, shunt obstruction, migration and infection,
low pressure headaches and subdural haematoma [67, 68].
An alternative to shunting is optic nerve sheath fenestration
(ONSF) [69] which is more cost effective in some health
care systems than CSF shunting [66]. But, this procedure
also has a 26% revision rate, due to closing over of the fen-
estration, with an ensuring rise in ICP and consequent po-
tential for further visual deterioration [66]. Headache
improvement after ONSF is variable (one third to one-half
have no headache response) [70].
The Neuro-Ophthalmology Research Disease Investi-
gator Consortium (NORDIC) are currently planning a
randomised controlled surgical trial, SIGHT, which will
compare shunting with ONSF and acetazolamide. The
trial will recruit patients with a severe visual loss defined
as a parametric mean deviation between -6 dB and
-27 dB assessed on the Humphrey visual field analyser.
Endovascular stenting
Venography brain imaging in IIH frequently demon-
strates venous sinus stenosis [55, 71]. These stenoses
typically regress after CSF drainage which induces re-
duction of ICP, consequently the stenoses are thought to
represent an effect of raised ICP not the underlying
cause [72]. The extent of the stenoses does not correlate
with ICP or predict the risk of visual loss [55]. Some
centres are conducting venous sinus stenting to treat
IIH but utility is debated. Case series have reported im-
provement in symptoms of intracranial hypertension,
however case selection is not randomised which can lead
to selection bias and there are a lack of long term out-
comes [73]. Complications of the procedure are reported
and include a short-lived ipsilateral headache in many,
Table 4 Medical conditions that may induce a secondary elevation
of ICP or produce symptoms that may mimic IIH (adapted from
[2, 25, 66–69])
1. Medical disorders that may induce a sinus vein thrombosis or that may
cause a venous outflow obstruction through other mechanisms:
• Thrombophilia and other hypercoagulable conditions
• Systemic lupus erythematodes
• Infections of the middle ear or mastoid
• CNS- infections
• Increased right heart pressure with pulmonary hypertension
• Chronic obstructive pulmonary disease
• Superior vena cava syndrome
• Arteriovenous fistulas
• Glomus tumour
• Tumour process that may compress parts of the venous outflow system
2. Medications
• Fluoroquinolones [70]
• Tetracycline
• Vitamin A and retinoids
• Anabolic steroids
• Withdrawal of corticosteroids (in particular after prolonged administration)
• Administration of growth hormone
• Lithium
• Nalidixic acid
• Oral contraceptives
• Levonorgestrel implant system
• Amiodarone
• Cyclosporine
• Cytarabine
3. Other medical conditions
• HIV
• Syphilis
• Borreliosis
• Varicella
• Addison’s disease
• Hypoparathyroidism
• Obstructive sleep apnoea
• Pickwickian syndrome
• Uraemia
• Severe iron deficiency anaemia
• Renal failure
• Turner syndrome
• Down syndrome
(See figure on previous page.)
Fig. 5 Optical coherence tomography highlighting worsening of papilloedema. OCT is useful for monitoring of changes in papilloedema. a, Right
eye infrared (IR) image of a normal small optic nerve in a patient in IIH with ocular remission. Note the tidemark changes of the extent of the
previous oedema. b, Colour photograph of right optic nerve with swelling and haemorrhage with recurrence of symptoms. c, Right eye IR image
taken at the same time as b. Note the extent of the oedema and the optic nerve is more visible with the OCT image compared to the photo. d,
Right eye cross-sectional image half way through the optic nerve head. Note the high line indicates the height of the swelling at this visit and
the red volume increase is from the last OCT scan to the most recent one. e, Left eye IR image of a normal small optic nerve in a patient in IIH
with ocular remission. Note the tidemark changes of the extent of the previous oedema. f, Colour photograph of left optic nerve with swelling
and cotton wool spot changes with recurrence of symptoms. g, Left eye IR image taken at the same time as f. Note the extent of the oedema
and the optic nerve is more visible with the OCT image compared to the photo. h, Left eye cross-sectional image half way through the optic nerve
head. Note the high line indicates the height of the swelling at this visit and the red volume increase is from the last OCT scan to the most recent one
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stent-adjacent stenosis that requires retreatment in a
third, and in rare cases vessel perforation leading to
acute subdural haematoma, stent migration, thrombosis
and death [73]. The comparative efficacy of stenting and
shunting is not established, nor are the long-term effi-
cacy, revision rate and safety data. There may be a role
in some highly selected IIH patients [74].
We do not advocate CSF diversion or shunting tech-
niques to treat isolated headache symptoms due to the
poor outcomes (ongoing headache in 68% at 6 months,
77% at 12 months and 79% at 2 years post-shunting),
high revision rates and risk of complications [67]. There
is insufficient evidence to support venous stenting to ex-
clusively treat headache.
Disease modification through weight loss
There is a clear association between IIH and weight with
over 90–95% of patients being obese [4]. Additionally,
IIH is reported in the context of gaining 5–15% of body
weight [75]. Weight loss is the only established disease
modifying therapy in IIH [76]. Consequently, patients
should be sensitively counselled about the importance of
weight loss. However, the amount of weight loss re-
quired is not well established. Additionally, the optimal
method of weight loss is uncertain. Dietary strategies are
notoriously difficult to achieve and maintain in the long term
[77, 78]. The role of bariatric surgery is being increasingly
suggested as a lasting therapy to induce IIH remission.
Bariatric surgery leads to greater weight loss compared
to dietary regimes, with mean reduction in body mass
index (BMI) of 7.05–15.34m/kg2 at 12 months [79] and
significant sustained long term weight loss [80]. Bariatric
surgery has been found to be cost effective for other obes-
ity related conditions with very low associated mortality
(0.05%–0.14%, which is akin to laparoscopic cholecystec-
tomy) [79, 81, 82]. A systematic review of the IIH cases
treated with bariatric surgery report 100% resolution of
papilloedema and 90% experience headache improvement
[83]. A randomised control trial evaluating bariatric sur-
gery in IIH is underway (IIH Weight Trial) [84].
Symptomatic therapy with therapeutics
Acetazolamide
Therapeutic agents currently used in IIH aim to reduce
ICP through reduction in CSF secretion. There are few
therapeutic options and the recent Cochrane review re-
ported: “the two included randomised controlled trials
showed modest benefits for acetazolamide for some out-
comes, there is insufficient evidence to recommend or
reject the efficacy of this intervention, or any other treat-
ments currently available, for treating people with IIH
[85]”. The IIHTT is the largest RCT to date and reports
improvement in visual field function in patients with
mild visual loss when treated with acetazolamide [86].
Benefits were most marked in those with the most
marked papilloedema. However high doses of acetazol-
amide were used (greater than 40% of patients were
treated with 4 g of acetazolamide daily) and this may not
be tolerable. Previous studies have demonstrated that
48% of patients discontinue acetazolamide when doses
of just 1500 mg are utilised [87]. Side effects include
paraesthesia, dysgeusia, vomiting and diarrhoea as well
as malaise, fatigue and depression [88, 89]. Acetazol-
amide is the only therapeutic that has been evaluated in
RCT and is regarded as the first line therapy for IIH.
However, not all clinicians prescribe acetazolamide for
IIH due to the limitations of the evidence base
highlighted by the 2015 Cochrane review in conjunction
with the potential side effect profile.
In pregnancy the use of acetazolamide is controversial.
Data from case series (n = 50 IIH patients using acet-
azolamide in the first trimester) has not identified an in-
creased risk of foetal malformations although animal
data has highlighted teratogenic effects [90, 91].
Alternative therapeutics
A number of alternative therapeutic agents are used in
IIH, however there is little evidence to support their use.
In animal studies, intravenous and intraventricular high
dose furosemide has been shown to reduce CSF secretion
by 20–50% [92–95]. However, clinically relevant routes of
delivery and dosing have not been studied. A paediatric
case series (n = 8) demonstrated that together acetazol-
amide and furosemide reduced ICP over 6 weeks, however
the absence of a control group limits interpretation [96].
Bumetamide does not reduce CSF secretion in animal
studies, and human studies have not been conducted [92].
Amiloride administered into the carotid artery in ani-
mal models reduces CSF secretion by up to 50% [97,
98]. But these studies have not used clinically relevant
doses or routes of delivery.
Octreotide has been hypothesised to manipulate CSF
secretion as there are somatostatin receptors on the
choroid plexus [99]. A prospective open-label study of
26 patients reported resolution of papilloedema in 92%
of cases however cautious interpretation is needed in the
absence of a control group [100].
Topiramate utility in IIH has been suggested by an
open label study which randomly assigned 40 patients to
acetazolamide or topiramate. They demonstrated treat-
ment equivalence with all patients experiencing im-
provement in visual fields (ICP was not measured) [101].
Topiramate may have additional advantages in IIH as it
can induce weight loss and has efficacy as a migraine
preventive therapy [102–105]. Recently reported in vivo
studies demonstrated that both subcutaneous and oral
administration of topiramate significantly lowers ICP in
rodents whilst other drugs tested, including
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acetazolamide, furosemide, amiloride and octreotide, did
not significantly reduce ICP [106].
Novel therapeutics
Future therapies would ideally control ICP acutely as well
as treat the underlying disease process through weight
loss. There is growing interest in the role of gut neuro
peptides in IIH. The gut peptide glucagon-like peptide-1
(GLP-1) regulates insulin secretion and weight, and cur-
rently GLP-1 mimetic drugs are used extensively to treat
diabetes (without risk of hypoglycaemia) and obesity
[107]. Recent in vitro assays have demonstrated that the
GLP-1 receptor agonist exendin-4 reduces CSF secretion
[108]. Additionally, clinically relevant doses of exendin-4
dramatically reduced ICP in rodents with raised ICP (44%
reduction in ICP within 10 min of dosing with effect
maintained for 24 h [108]. A clinical trial is currently un-
derway exploring the physiological effects of exenatide in
reducing ICP in IIH.
Therapeutic agents inhibiting the actions of 11Beta hy-
droxysteroid dehydrogenase type 1 (11β-HSD1) have
been proposed in IIH. 11β-HSD1 is an enzyme which
converts inactive cortisone to active cortisol and conse-
quently regulates local cortisol availability, a key deter-
minant of fluid secretion [109]. 11β-HSD1 inhibitors
have been shown to reduce intraocular pressure through
reduction of aqueous humour production by the ocular
ciliary body [110]. Akin to this mechanism, 11β-HSD1 is
functionally active in the CSF secreting choroid plexus
epithelial cells [111]. In patients with IIH, reduction in
ICP correlates with reduction in global 11β-HSD1 activ-
ity measures [111]. 11β-HSD1 inhibitors have been de-
veloped to treat obesity and metabolic syndrome. A
phase 2 randomised controlled trial has been conducted
in IIH which assesses a specific 11β-HSD1 inhibitor
(AZ4017), results are awaited [112].
Managing headache
Headache is the predominant morbidity in IIH and sig-
nificantly reduces quality of life [9]. Headaches occur
not only during the active stages of the disease when
ICP is elevated, but frequently continue even after the
ICP has settled [10, 67]. In those IIH patients with re-
solved papilloedema (IIH in ocular remission), the on-
going headaches cause significant morbidity. Evidence to
guide headache management is very limited. Principles
of managing headache in IIH could include [113]:
1. In those IIH patients with ongoing raised ICP,
weight loss has been shown to significantly improve
the Headache Impact Test 6 score (HIT-6) as well
as headache severity, frequency and acute analgesic
use [114]. Interestingly acetazolamide does not
improve headache disability scores on the HIT-6 [86].
2. Medication-overuse headaches are a frequent
co-morbidity in IIH (37%) and patients will likely
benefit from withdrawal [11].
3. Headache phenotype should be carefully evaluated
to look for features of co-existing migraine. In those
with IIH in ocular remission and migraine or in
those with migraine-like headache with active IIH,
acute and preventive strategies may be useful
although there are no dedicated studies in this area.
Preventive strategies may have particular benefit for
those patients in whom the ICP is settling (IIH in
ocular remission). Choice of migraine prevention
should consider avoiding drugs that induce weight
gain. Potential choices could include topiramate,
candesartan and onabotulinum toxin A, although
there is no evidence of efficacy of these drugs in the
setting of IIH [113, 115].
Therapeutic lumbar puncture
Therapeutic serial LPs are not advocated as a long-term
treatment strategy for IIH. Although LP induces a tran-
sient reduction of CSF pressure the effect is typically
short lived with pressures rising rapidly after the proced-
ure [116]. Therapeutic LP has limited application for
managing headache, as headache improves in 71%, but
the improvement is small (1 point on the verbal rating
score 0–10) and there is also a 64% chance of a head-
ache exacerbation in the week following LP in IIH pa-
tients [117]. Additionally, IIH patients frequently report
a very negative and emotional experience when they
undergo a LP [118, 119]. In the short term, LP may have
a role as a temporising procedure to preserve vision in
patients with fulminant IIH awaiting an imminent CSF
diversion procedure.
Pregnancy
Pregnancy can potentially limit the ability to perform
neuroimaging studies for investigation and restrict thera-
peutic options. Hence the management of those who ei-
ther present in pregnancy for the first time with IIH or
for the majority who become pregnant during the course
of their disease management should be determined on a
case-by-case basis [120–122].
Patients should be cautioned about excessive weight gain
during pregnancy that could precipitate a worsening of
their IIH. If there is access to a weight management service,
this is useful so that clear advice regarding weight gain is
appropriate for the gestational age of the foetus [123].
Use of acetazolamide in pregnancy is controversial,
and should be discussed with the individual as perinatal
exposure in rodents has caused teratogenic effects [124,
125]. The postaxial limb deformities, such as polydactyly
or limb deficiency, that have been reported in small ani-
mals were not found in primate studies [126]. The
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manufacturers do not recommend its use in pregnancy,
but some have reported using it in other conditions and
the risk of malformation was no higher than expected in
the general population however few patients had expos-
ure in the first trimester [127]. In the largest study on
the use of acetazolamide in IIH, 101 pregnant women
(158 pregnancies) took acetazolamide in a daily dose
ranging between 250 and 2000 mg. Over half took acet-
azolamide prior to 13th gestational week, abortion rate
(both spontaneous and induced) was higher in the acet-
azolamide group; the authors therefore recommended
that acetazolamide should be used with caution and jus-
tification in the pregnant IIH patient [91].
Topiramate should not be used in pregnancy, due to
the clear higher rate of foetal abnormalities following its
use [128]. Many other headache treatments are not rec-
ommended in pregnancy; therefore the risk-benefit
should be discussed with the patient.
Few patients present with IIH in pregnancy, and if there
is imminent risk to the vision, serial LPs, optic nerve
sheath fenestration or CSF diversion can be considered
[120, 129]. Clear communication with the obstetric and
gynaecological services is key to help reassure healthcare
professionals and the patient. Increased observations dur-
ing pregnancy also serves to reassure. Alterations to birth
plans should not be made on the basis of the historical
diagnosis of IIH and only if there is likely to be precipitous
visual decline in the settling of moderate to severe papilloe-
dema. If there is a potential for a prolonged second stage of
labour assisted deliveries (such as caesarean section or in-
strumental deliveries) should be considered.
Idiopathic intracranial hypertension without Papilloedema
(IIHWOP)
This is a rare form of IIH where there is no evidence of
papilloedema in the setting of raised ICP. Headache is
the principle morbidity in these patients.
The diagnostic criteria for definite IIHWOP are the
same as for IIH, except there is no papilloedema, but
unilateral or bilateral sixth nerve palsies may be present.
A diagnosis of possible IIHWOP can be made without
the presence of unilateral or bilateral sixth nerve palsies,
however in this case at least 3 out of the following 4 fea-
tures on brain imaging need to be present: an empty
sella, flattening of the eye globe, widening of the space
around the optic nerve and/or transverse venous sinus
stenosis [2]. In patients with IIHWOP risk of vision loss
has not been identified and does not seem to develop
over the disease course. The commonest symptoms of
IIHWOP include headache, pulsatile tinnitus, visual phe-
nomena such as visual obscurations, blurred vision,
photopsia and diplopia (due to sixth nerve palsy) [27].
Once a diagnosis of IIHWOP is established, all patients
should be counselled about weight management. As there
is no threat to vision, long term visual monitoring is not re-
quired. Management of headache should be the same as in
IIH. Escalation of management to surgery to control ele-
vated ICP in IIHWOP should not be routinely considered.
Conclusion
IIH is a challenging disease which crosses many specialties.
At investigation it requires careful exclusion of secondary
causes through history, neuroimaging, LP and ophthalmic
examination. Once a diagnosis is established of typical IIH,
it requires regular visual monitoring, neurological input for
active headache management, and direct conselling regard-
ing weight loss. When there is no immediate threat to vi-
sion, medical treatment with acetazolamide should be
considered. Less commonly required are surgical treat-
ments to preserve vision when fulminant IIH exists. There
is increasing research in this area and as evidence is pub-
lished this document will require timely revision.
Additional file
Additional file 1: This is an infrared 10 s video as taken with the
Heidelberg Engineering™ optical coherence tomography instrument.
There is clear evidence of spontaneous venous pulsation at the optic
nerve head in a normal person. The veins at the optic nerve head cup
move in and out, with colour and shape change. (MOV 4666 kb)
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